Yes — comprehensive cancer cover is a core part of all leading UK private health insurance policies, and for many people it’s the single biggest reason to buy cover. It typically pays in full for diagnosis, surgery, chemotherapy, radiotherapy and specialist consultations for cancers that arise after your policy starts. The important exceptions are a cancer you’d already had or been investigated for before buying (usually excluded as pre-existing), and screening of people with no symptoms (not covered). Cover levels and especially cancer drug access vary between insurers, so the detail matters.

On a comprehensive policy, typically: rapid diagnosis and staging (scans, biopsies), surgery, chemotherapy, radiotherapy, and increasingly targeted therapy, immunotherapy and biological agents for the duration of active treatment. Most policies also cover post-treatment monitoring and palliative care, and many add support services — a dedicated cancer nurse line, mental health support, and contributions toward wigs or prostheses. The biggest variable is cancer drugs: whether the policy funds treatments not routinely available on the NHS (see the non-NICE drug question below).

No — and this is the most important difference when comparing cancer cover. Some insurers (Bupa and AXA among them) will fund cancer drugs that are licensed in the UK but not approved by NICE for NHS use, letting your oncologist prescribe newer targeted or second-line treatments. Others cover a narrower, more NICE-aligned formulary. For anyone with a family history or specific cancer concern, this non-NICE drug access is arguably the dominant factor in choosing a policy — it’s where private cover can most exceed what the NHS routinely funds.

It’s difficult but not always impossible. A previous cancer diagnosis is one of the most common reasons for a policy exclusion — on full medical underwriting an insurer will often place a permanent or long-term exclusion on that cancer and sometimes related conditions. On moratorium underwriting, conditions from the last five years are excluded but may become eligible after a continuous symptom-free, treatment-free period (typically two years), though cancer is often treated more cautiously. A specialist broker is genuinely valuable here — some insurers view cancer history more favourably than others.

Comprehensive cover including full cancer treatment typically costs from around £40–£120+ a month for an individual, depending heavily on age, location, excess and how comprehensive the cancer drug cover is. Policies with broad non-NICE drug access sit at the higher end. You can lower the premium with a higher excess, a guided consultant option or a narrower hospital list — but be cautious about cutting cancer cover itself to save money, since it’s usually the benefit people value most. Always compare like-for-like on cancer terms specifically.

Generally no. Private medical insurance covers investigation and treatment of symptoms, not routine screening of people who feel well — so a mammogram, PSA test or private scan you request without symptoms is usually self-funded, like a health MOT. The line is symptoms: if you have a symptom your GP refers for investigation, that diagnostic pathway is typically covered; asymptomatic screening isn’t. This is a common point of confusion, and it applies to cancer screening as it does to all screening.

The NHS provides excellent cancer care, free — so private cover isn’t about survival, and it’s honest to say so. What it buys is speed (faster diagnosis and treatment start, which can matter), choice of consultant and hospital, private facilities, and crucially access to some licensed drugs the NHS doesn’t routinely fund. For people who want that speed and drug flexibility and can afford the premium, it’s often the main reason they hold cover; for others, the NHS remains a strong safety net. It’s a personal value judgement, not a clinical necessity.